Point-of-Care Diagnostics Market for Infectious Diseases, 2020-2025

NEXT STORY
SELLAS Announces Positive Follow-up Data from the Randomized Phase 2 VADIS Trial of Nelipepimut-S (NPS) in Women with Ductal Carcinoma In-Situ of the Breast
PREV STORY
Rhythm Pharmaceuticals Announces Appointments of Camille L. Bedrosian, M.D., and Lynn Tetrault, J.D., to its Board of Directors
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Point-of-Care Diagnostics Market for Infectious Diseases, 2020-2025

NEXT STORY
SELLAS Announces Positive Follow-up Data from the Randomized Phase 2 VADIS Trial of Nelipepimut-S (NPS) in Women with Ductal Carcinoma In-Situ of the Breast
PREV STORY
Rhythm Pharmaceuticals Announces Appointments of Camille L. Bedrosian, M.D., and Lynn Tetrault, J.D., to its Board of Directors
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Kura Oncology Granted U.S. Patent for Clinical-Stage ERK Inhibitor, KO-947

LA JOLLA, Calif., April 19, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a ...

author_avatar
NASDAQ Market News

Asterias Biotherapeutics Announces Independent Data Monitoring Committee Completes Last Intermediate Review of AST-OPC1 Clinical Trial in Acute Spinal Cord Injury

- AST-OPC1 Safety Profile Continues To Be Favorable - FREMONT, Calif., June 05, 2018 ...

author_avatar
NASDAQ Market News

AzurRx BioPharma Announces Successful Phase IIa Trial of MS1819-SD in Exocrine Pancreatic Insufficiency

NEW YORK, June 29, 2018 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or ...

author_avatar
NASDAQ Market News